<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>All About Cardiovascular System and Disorders</provider_name><provider_url>https://johnsonfrancis.org/professional</provider_url><author_name>Johnson Francis</author_name><author_url>https://johnsonfrancis.org/professional/author/jf/</author_url><title>Finerenone, a non-steroidal MRA - All About Cardiovascular System and Disorders</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="Frn7xhpOjm"&gt;&lt;a href="https://johnsonfrancis.org/professional/finerenone-a-non-steroidal-mra/"&gt;Finerenone, a non-steroidal MRA&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://johnsonfrancis.org/professional/finerenone-a-non-steroidal-mra/embed/#?secret=Frn7xhpOjm" width="600" height="338" title="&#x201C;Finerenone, a non-steroidal MRA&#x201D; &#x2014; All About Cardiovascular System and Disorders" data-secret="Frn7xhpOjm" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://johnsonfrancis.org/professional/wp-includes/js/wp-embed.min.js
&lt;/script&gt;
</html><thumbnail_url>https://johnsonfrancis.org/professional/wp-content/uploads/2022/09/Finerenone-a-non-steroidal-MRA.jpg</thumbnail_url><thumbnail_width>1211</thumbnail_width><thumbnail_height>675</thumbnail_height><description>Finerenone, a non-steroidal MRA Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist. Finerenone is thought to have lower risk of hyperkalemia and renal issues compared to other MRAs. It has been shown to reduce albuminuria in patients with chronic kidney disease and type 2 diabetes mellitus. FInerenone in reducing kiDnEy faiLure and dIsease prOgression in [&hellip;]</description></oembed>
